Race Oncology has announced that it has signed an agreement to conduct a trial of…
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access to key resources related to the data read out.
Announcement highlights:
Summary of resources:
Investors are invited to access the following resources related to the data read out:
In its Dr Boreham’s Crucible weekly column, Biotech Daily covered the trial in detail. To view a copy of that article, please click here.